Amarin Corporation plc

Contributing Author

Recent Articles by Amarin Corporation plc

Aug-31	Amarin Highlights New REDUCE-IT and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026 AMRN GlobeNewswire
Aug-28	New REDUCE-IT Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients AMRN GlobeNewswire
Aug-24	New Analyses from REDUCE-IT and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026 AMRN GlobeNewswire
Jul-29	Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence AMRN GlobeNewswire
Jul-15	Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026 AMRN GlobeNewswire
Jun-30	Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape AMRN GlobeNewswire
May-27	New REDUCE-IT Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia AMRN GlobeNewswire
Apr-29	Amarin Reports 2026 First Quarter Financial Results AMRN GlobeNewswire
Apr-15	Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 AMRN GlobeNewswire
Apr-08	American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction AMRN GlobeNewswire
Mar-18	Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline AMRN GlobeNewswire
Mar-16	New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo AMRN GlobeNewswire
Mar-02	Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT Post Hoc Analysis Published in the European Journal of Preventive Cardiology AMRN GlobeNewswire
Feb-25	Amarin Reports Fourth Quarter and Full Year 2025 Financial Results AMRN -9.47% GlobeNewswire
Feb-23	This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease AMRN GlobeNewswire
Feb-11	Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 AMRN GlobeNewswire
Jan-09	Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA/VAZKEPA (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization AMRN GlobeNewswire
Jan-08	Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities AMRN +16.89% GlobeNewswire
Nov-09	New REDUCE-IT Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA/VAZKEPA (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients AMRN GlobeNewswire
Nov-03	Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025 AMRN GlobeNewswire
Oct-29	Amarin Reports Third Quarter 2025 Financial Results AMRN -11.25% GlobeNewswire
Oct-27	Amarin Issues Statement Supporting FDA's Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit AMRN GlobeNewswire
Oct-15	Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025 AMRN GlobeNewswire
Oct-14	Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT and EPA Mechanistic Data at the Canadian Cardiovascular Congress AMRN GlobeNewswire
Aug-31	Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025 AMRN GlobeNewswire
Aug-30	New REDUCE-IT Analyses Presented at ESC 2025 Include Data Showing VASCEPA/VAZKEPA (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups AMRN GlobeNewswire
Aug-25	New Analyses from REDUCE-IT and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025 AMRN GlobeNewswire
Jul-30	Amarin Reports Second Quarter 2025 Financial Results AMRN GlobeNewswire
Jul-23	Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025 AMRN GlobeNewswire
Jun-24	Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA (Icosapent Ethyl) in Europe AMRN +27.26% GlobeNewswire
May-07	Amarin Reports First Quarter 2025 Financial Results AMRN GlobeNewswire

Amarin Corporation plc

Recent Articles by Amarin Corporation plc

Upgrade your Finviz experience